MARKET

NNVC

NNVC

Nanoviricides
AMEX

Real-time Quotes | Nasdaq Last Sale

2.070
-0.140
-6.33%
Opening 10:51 05/24 EDT
OPEN
2.060
PREV CLOSE
2.210
HIGH
2.090
LOW
1.990
VOLUME
53.31K
TURNOVER
53.06K
52 WEEK HIGH
7.86
52 WEEK LOW
1.040
MARKET CAP
23.92M
P/E (TTM)
-2.7013
1D
5D
1M
3M
1Y
5Y
58 Biggest Movers From Yesterday
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.
Benzinga · 5h ago
HIVE, XIN and NEON among mid-day movers
Gainers: Lixiang Education Holding (LXEH) +62%. GeoVax Labs (GOVX) +50%. Sonder Holdings (SOND) +30%. O2Micro International (OIIM) +30%. Evolving Systems (OTC:EVOL) +28%. GoldMining (GLDG) +27%. Neonode (NEON) +24%. Mesa Royalty
Seekingalpha · 22h ago
30 Stocks Moving In Monday's Mid-Day Session
Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday.
Benzinga · 23h ago
Mid-Morning Market Update: Markets Mixed; Broadcom In Talks To Buy VMWare
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 250 points on Monday.
Benzinga · 1d ago
GeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers' pack
Gainers: GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Allarity Therapeutics (ALLR) +14%. Tonix Pharmaceuticals (TNXP) +13%. TRxADE HEALTH (MEDS) +13%. Losers: Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%. NanoViricides (NNVC) -19%. Brig...
Seekingalpha · 1d ago
24 Stocks Moving in Monday's Pre-Market Session
Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday.
Benzinga · 1d ago
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Benzinga · 1d ago
NNVC, BEST and PYR among mid-day movers
Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%.
Seekingalpha · 3d ago
More
No Data
Learn about the latest financial forecast of NNVC. Analyze the recent business situations of Nanoviricides through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NNVC stock price target is 8.50 with a high estimate of 8.50 and a low estimate of 8.50.
High8.50
Average8.50
Low8.50
Current 2.070
EPS
Actual
Estimate
-0.18-0.14-0.09-0.05
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 38
Institutional Holdings: 3.05M
% Owned: 26.37%
Shares Outstanding: 11.55M
TypeInstitutionsShares
Increased
3
85.77K
New
2
25.06K
Decreased
6
173.75K
Sold Out
4
1.42M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.74%
Pharmaceuticals & Medical Research
-0.42%
Key Executives
Chairman/President/Director
Anil Diwan
Chief Financial Officer
Meeta Vyas
Independent Director
Stanley Glick
Independent Director
Makarand Jawadekar
Independent Director
Theodore Rokita
Independent Director
Brian Zucker
No Data
No Data
About NNVC
NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash.

Webull offers kinds of NanoViricides Inc stock information, including AMEX:NNVC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NNVC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NNVC stock methods without spending real money on the virtual paper trading platform.